Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Simkins

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|May 29, 2012
Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout miceTyrell J Simkins, Kelly L Janis, Alison K McClure, et al.
Osteoarthritis and Cartilage|July 20, 2024
People with short symptom duration of knee osteoarthritis benefit more from exercise therapy than people with longer symptom duration: An individual participant data meta-analysis from the OA trial bankM van Middelkoop, D Schiphof, M Hattle, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 9, 2016
Pretransplant CD4 Count Influences Immune Reconstitution and Risk of Infectious Complications in Human Immunodeficiency Virus-Infected Kidney Allograft RecipientsJ F Suarez, R Rosa, M A Lorio, et al.
Osteoarthritis and Cartilage|September 1, 2024
Knee braces for knee osteoarthritis: A scoping review and narrative synthesis of interventions in randomised controlled trialsM A Holden, M Murphy, J Simkins, et al.
European Heart Journal|March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyAlbree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|May 29, 2012
Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout miceTyrell J Simkins, Kelly L Janis, Alison K McClure, et al.
Osteoarthritis and Cartilage|July 20, 2024
People with short symptom duration of knee osteoarthritis benefit more from exercise therapy than people with longer symptom duration: An individual participant data meta-analysis from the OA trial bankM van Middelkoop, D Schiphof, M Hattle, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 9, 2016
Pretransplant CD4 Count Influences Immune Reconstitution and Risk of Infectious Complications in Human Immunodeficiency Virus-Infected Kidney Allograft RecipientsJ F Suarez, R Rosa, M A Lorio, et al.
Osteoarthritis and Cartilage|September 1, 2024
Knee braces for knee osteoarthritis: A scoping review and narrative synthesis of interventions in randomised controlled trialsM A Holden, M Murphy, J Simkins, et al.
European Heart Journal|March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyAlbree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Pageof 3